Lee et al, 1 comprising authors from a number of institutions, published a retrospective observational study conducted on 147 consecutive patients who underwent endoscopic enucleation of the prostate ...

Alicia Morgans is joined by Alan Dal Pra and George Zhao to discuss updates to the PORTOS Trial. PORTOS is a gene signature developed to predict radiation therapy benefit in prostate cancer, built on ...

Immunohistochemical Expression of Nectin-4 and Potential Implications for Enfortumab Vedotin Therapy in Germ Cell Tumors of the Testis: A Preliminary Study - Beyond the Abstract ...

Inherited Defects of piRNA Biogenesis Cause Transposon De-Repression, Impaired Spermatogenesis, and Human Male Infertility - Beyond the Abstract ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

ASCO 2025 Press Releases Johnson & Johnson Leads with First PARP Inhibitor Combo to Improve Efficacy in Patients with HRR-altered mCSPC ImmunityBio Receives FDA Expanded Access Authorization for ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

The Kurt extraperitoneal ligamentopexy: A new surgical method with uterine preservation for pelvic organ prolapse, "Beyond the Abstract," by Sefa Kurt and Mehmet Tunc Canda ...

26th Annual Meeting of the Society of Urologic Oncology (SUO 2025) Dec 02, 2025 - Dec 05, 2025 Society of Urologic Oncology, SUO 2025, urology conferences, phoenix conferences.

ASCO GU 2026 race and community-level social vulnerability influence risk-based prostate cancer treatment patterns and metastasis-free survival.

ASCO GU 2024 Press Releases Photocure Partner Asieris Presented Clinical Trial and Real-World Data on Hexvix in China at ASCO GU 2024 Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% ...

Tumor suppressor genes play a critical role in prostate cancer progression, with alterations in PTEN, TP53, and RB1 representing some of the most clinically significant genomic events. These ...